www.neuralymed.com
Open in
urlscan Pro
198.185.159.144
Public Scan
Submitted URL: http://neuralymed.com/
Effective URL: https://www.neuralymed.com/
Submission: On October 02 via api from US — Scanned from DE
Effective URL: https://www.neuralymed.com/
Submission: On October 02 via api from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact WE DISCOVER AND DEVELOP REVOLUTIONARY TREATMENTS FOR NEURODEGENERATIVE DISEASES WE’RE IN THE BUSINESS OF OFFERING NEW HOPE. Neuraly was founded to develop new drugs that change our expectations about successful treatment of progressive diseases like Alzheimer’s and Parkinson’s. We are developing drugs that address new pathways, capitalize on our founder’s innovation, and deliver medicines with the potential to change lives. Learn More OUR SCIENTIFIC PLATFORM Read about the science behind our approach to treating neurodegenerative diseases. Learn More OUR PIPELINE Our clinical development strategy focuses on the inhibition of pathological glial activation and its role in preventing neuronal cell death. View Programs OUR EFFORTS ARE THE WORK OF MANY HANDS. Our world-class team is composed of innovators and trailblazers, committed to finding a cure where no disease-modifying therapies exist. Meet the Team JOIN A TEAM THAT LIVES TO IMPROVE LIVES. From the beginning, Neuraly has been a team of dedicated and passionate professionals. We pride ourselves on a culture of curiosity and creative problem solving as we leap toward a future where people with severe neurodegenerative diseases are living fulfilled lives. Eager to join us on our journey? Explore Opportunities NEURALY IN THE NEWS OCT 19, 2021 D&D PHARMATECH RAISES $51M IN SERIES C FINANCING TO ADVANCE POTENTIAL DISEASE-MODIFYING TREATMENTS FOR NEURODEGENERATIVE, FIBROTIC, AND METABOLIC DISEASES D&D Pharmatech, a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and parent company of U.S.-based Neuraly Inc., Precision Molecular, Inc… Full Article APR 28, 2021 NEURALY ANNOUNCES PUBLICATION IN ACTA NEUROPATHOLOGICA COMMUNICATIONS OF PRECLINICAL DATA DETAILING THE NEUROPROTECTIVE EFFECT OF NLY01 IN MODELS OF ALZHEIMER’S DISEASE NLY01 selectively blocks β-amyloid-induced activation of microglia through upregulated GLP-1R. Neuronal viability was preserved, resulting in improved spatial learning and memory Full Article MAR 3, 2020 NEURALY ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF NLY01 FOR PATIENTS WITH PARKINSON’S DISEASE Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease. Full Article View All Articles Privacy Policy © Copyright 2021, Neuraly Inc 704 Quince Orchard Road #320 Gaithersburg, MD 20878 301.658.6100 info@neuralymed.com